Covid-19: Mubadala unit helps fund UK drug trial for diabetics
- Date: 09-Nov-2020
- Source: Emirates Business
- Sector:Financial Markets
- Country:UAE
Covid-19: Mubadala unit helps fund UK drug trial for diabetics
Admin 12 hours ago Local News
Abu Dhabi / WAM
In line with its drive to strengthen the UAE's leading role in fight against Covid-19 pandemic on an international scale, Mubadala Healthcare is part-funding the trial of an immune-dampening drug in the UK that will help patients with diabetes overcome effects of the virus. If successful, the compound could ultimately be prescribed by a primary care physician for people with diabetes presenting with early symptoms of coronavirus.
The UK's Medicines and Healthcare products Agency approved the trial, known as ARCADIA, following preclinical research that suggests a glucose kinase activator (AZD1656) could help diabetes patients with Covid-19 by dampening the overactive response of the immune system that is typically acute in those patients with raised blood glucose levels. The trial commenced on
Select Sector 
Select Country 
